Active Filter(s):
Details:
Advanced BioDesign will finalise its preclinical studies and submit a clinical trial authorization to start clinical phase I in AML in early 2021.
Lead Product(s): ABD-3001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Xerys Funds
Deal Size: $9.8 million Upfront Cash: Undisclosed
Deal Type: Funding February 26, 2020